{"id":"NCT01428661","sponsor":"Vanda Pharmaceuticals","briefTitle":"Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder","officialTitle":"MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-09","primaryCompletion":"2013-01","completion":"2013-05","firstPosted":"2011-09-05","resultsPosted":"2015-06-19","lastUpdate":"2015-06-19"},"enrollment":507,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"tasimelteon","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"tasimelteon","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.","primaryOutcome":{"measure":"Change From Baseline to Endpoint at Week 8 Using the Total Score of the Hamilton Depression Rating Scale (HAM-D)","timeFrame":"8 weeks","effectByArm":[{"arm":"Tasimelteon","deltaMin":-8.19,"sd":0.45},{"arm":"Placebo","deltaMin":-7.83,"sd":0.45},{"arm":"Open Label Tasimelteon","deltaMin":-13.6,"sd":0.34}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":40,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":254},"commonTop":["Headache","Nasopharyngitis","Upper Respitory Tract Infection","Somnolence","Diarrhoea"]}}